Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)

Sponsor
Barbara Ann Karmanos Cancer Institute (Other)
Overall Status
Completed
CT.gov ID
NCT01420874
Collaborator
(none)
15
Enrollment
1
Location
1
Arm
110.1
Duration (Months)
0.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this research study is for the participant to give their own T cells (a type of blood cell in the body that can fight infections and possibly cancer) to them after they have been removed, grown in a lab, and then coated with an experimental drug.

This study will determine the highest dose of EGFR2Bi coated T cells that can be given without causing severe side effects. Initially a group of 3 participants will receive the same dose of study drug. If no serious side effects occur, the next group of participants will receive a slightly higher dose of study agent. The following groups of participants will receive higher doses of the study drug until a dose is reached where there are unacceptable side effects and maximum tolerated dose is found, or the planned highest dose level is reached with no side effects.

Detailed Description

The purpose of this study is to determine in a dose-escalation phase Ib trial the safety of 3 infusions of EGFR2Bi armed activated T cells (aATC), after chemotherapy, for patients with advanced colorectal and pancreatic cancer

Study Design

Study Type:
Interventional
Actual Enrollment :
15 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Treatment of Advanced Colorectal or Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Armed Activated T-Cells (Phase Ib)
Study Start Date :
Aug 17, 2011
Actual Primary Completion Date :
Oct 19, 2020
Actual Study Completion Date :
Oct 19, 2020

Arms and Interventions

ArmIntervention/Treatment
Experimental: FOLFOX6 & EGFRBi armed ATC Infusions

FOLFOX6: IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, & in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo. EGFRBi armed ATC Infusions: Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion

Drug: FOLFOX6
IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, & in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.
Other Names:
  • leucovorin (FOLinic acid)
  • Fluorouracil
  • OXaliplatin
  • Biological: EGFRBi armed ATC Infusions
    Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion

    Outcome Measures

    Primary Outcome Measures

    1. Determining in a dose-escalation phase Ib trial the safety of 3 infusions of EGFR2Bi aATC, and a booster infusion after 3 months, for patients with advanced colorectal or pancreatic cancer. [4 wks after chemo, prior to ATC infusion #2; 1 wk later prior to ATC infusion #3; Wks 2, 4 & 9 post ATC infusion #3; Wk 8 post ATC #4 (booster)]

      Participants will be assessed for changes in lab values (CBC, Sodium, potassium, calcium, magnesium, chloride, bicarbonate, glucose,BUN, creatinine, total Protein, albumin, total bilirubin, ALP, AST,ALT, CEA or CA 19-9.

    Secondary Outcome Measures

    1. Determining whether IMT enhances anti-tumor immunity;Cytokine resp., phenotypic markers, anti-tumor cytotoxicity, in vivo and in vitro specific anti-tumor antibody prod. & molecular signaling markers of T-cell activation assessed before chemo & after IMT [3 weeks after chemo prior to ATC infusion #1; At wks 4(ATC #2) & 5 (ATC #3) post chemo; wks 2 , 4 & 9 post ATC #3 infusion; Day of ATC #4 (booster infusion), then wks 2, 4 & 8; & mon 6 and 1yr post ATC #4 (booster infusion)]

      Immune studies: Serum cytokine responses will be quantified focus on the levels of those factors known to be important regulators of T cell responses. Phenotype analysis will measure the percent of T, B, NKT and NK cells in peripheral blood mononuclear cell (PBMC) and tumor-infiltrating lymphocyte (TIL) samples. T cell proportions would be further analyzed by subset (CD4, CD8, CD25+). Cytotoxicity is measured in percentage in PBMC.

    2. Determining the tumor response rate [Approximately every 8 weeks to until 1 year]

      CT or PET Scan

    3. Overall Survival [Approximately every 8 weeks to until 1 year]

      CT or PET Scan

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Histological or cytological proof of colorectal or pancreatic adenocarcinoma

    • Must have metastatic colorectal cancer or pancreatic cancer with stable disease after first line chemotherapy or patients with colorectal or pancreatic cancer who have progressed with standard chemotherapy options*

    • Standard chemotherapy for metastatic colorectal cancer include 5-FU/capecitabine with either oxaliplatin or irinotecan based regimen with or without bevacizumab or cetuximab.

    • Standard chemotherapy for metastatic pancreatic cancer include gemzar based regimen or FOLFIRINOX (5-FU, oxaliplatin, and irinotecan)

    • Prior cetuximab, panitumumab, or other monoclonal antibody therapy allowed if given 28 days prior to the 1st infusion of armed T cells

    • Absolute Neutrophil Count (ANC) ≥ 1,000/mm3

    • Lymphocyte count ≥ 400/mm3

    • Platelet Count ≥ 50,000/mm3

    • Hemoglobin ≥ 8 g/dL

    • Serum Creatinine < 2.0 mg/dl, Creatinine Clearance ≥50 ml/mm (can be calculated)

    • Total Bilirubin ≤ 2 mg/dl (biliary stent is allowed)

    • SGPT and SGOT < 5.0 times normal

    • LVEF ≥ 45% at rest (MUGA or Echo)

    • Pulse Oximetry of >88%

    • Age ≥ 18 years at the time of consent

    • Written informed consent and HIPAA authorization for release of personal health information

    • Females of childbearing potential, and males, must be willing to use an effective method of contraception

    • Females of childbearing potential must have a negative pregnancy test within 7 days of being registered for protocol therapy

    • KPS ≥ 70% or SWOG Performance Status 0 or 1

    Exclusion Criteria:
    • Any chemotherapy related toxicities from prior treatment.(> grade I per CTCAE v4.0

    • Known hypersensitivity to cetuximab or other EGFR antibody

    • Treatment with any investigational agent within 14 days prior to being registered for protocol therapy Protocol version: 07/13/2011 8

    • Symptomatic brain metastasis

    • Chronic treatment with systemic steroids or another immuno-suppressive agent

    • Serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to being registered for protocol therapy

    • Active liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis

    • HIV infection

    • Positive HbsAg

    • Positive Hepatitis C

    • Active bleeding or a pathological condition that is associated with a high risk of bleeding

    • Uncontrolled systemic disease like active infections

    • Nonmalignant medical illnesses that are uncontrolled or a controlled illness that may be jeopardized by the treatment with protocol therapy

    • Females must not be breastfeeding

    • Patient may be excluded if, in the opinion of the PI and investigator team, the patient is not capable of being compliant

    Minor changes from these guidelines will be allowed at the discretion of the attending team under special circumstances. The reasons for exceptions will be documented.

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Barbara Ann Karmanos Cancer InstituteDetroitMichiganUnited States48601

    Sponsors and Collaborators

    • Barbara Ann Karmanos Cancer Institute

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Anthony F. Shields, MD PhD, Principal Investigator, Barbara Ann Karmanos Cancer Institute
    ClinicalTrials.gov Identifier:
    NCT01420874
    Other Study ID Numbers:
    • 2011-025
    First Posted:
    Aug 22, 2011
    Last Update Posted:
    Apr 7, 2022
    Last Verified:
    Mar 1, 2022

    Study Results

    No Results Posted as of Apr 7, 2022